Robert Bristow
The Philip J. DiSaia Chair, Gynecologic Oncology
School of Medicine
School of Medicine
Professor, Obstetrics & Gynecology
School of Medicine
School of Medicine
Chair
School of Medicine
School of Medicine
M.D., University of Southern California, 1991
M.B.A., Johns Hopkins University, 2009
M.B.A., Johns Hopkins University, 2009
University of California, Irvine
333 City Boulevard West
14th Floor, Suite 1400
Mail Code: 3200
Orange, CA 92868
333 City Boulevard West
14th Floor, Suite 1400
Mail Code: 3200
Orange, CA 92868
Research Interests
Health care outcomes and patterns of care for women with cancer of the ovary and endometrium
Websites
Academic Distinctions
UNDERGRADUATE
Pomona College Scholar
1984, 1985
Associate Member Sigma Xi National Research Society
1987
MEDICAL SCHOOL
Dean’s Award for Academic Excellence
1988, 1989, 1990
Dean’s Scholarship for Academic Merit
1989
Alpha Omega Alpha
1990
Franklin C. McLean Scholar National Medical Fellowships
1990
RESIDENCY
Administrative Chief Resident
1994-1995
Excellence in Teaching Award
1995
PROFESSIONAL
CREOG Resident Education Award
The Johns Hopkins Hospital
Department of Gynecology and Obstetrics
2002, 2004
Excellence in Resident Education & Mentoring
The Johns Hopkins Hospital
Department of Gynecology and Obstetrics
2005, 2007, 2009
Philip J. DiSaia Prestigious Chair in Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Irvine – Medical Center
2012
Associated Medical Students Golden Apple Award
University of California, Irvine – School of Medicine
2013, 2014
Annual Kirk A. Keegan Jr. Teaching Award
University of California, Irvine
Department of Obstetrics and Gynecology
2013, 2014
OTHER PROFESSIONAL RECOGNITION
Baltimore’s Top Doctors – Gynecologic Oncology
2002, 2006
Castle Connolly America’s Top Doctor
2009, 2010
Best Doctors in America
2009, 2010
US News and World Report – Top Doctor
2011 - 2013
Showmark America’s Top Physician for Cancer
2013, 2014
Pomona College Scholar
1984, 1985
Associate Member Sigma Xi National Research Society
1987
MEDICAL SCHOOL
Dean’s Award for Academic Excellence
1988, 1989, 1990
Dean’s Scholarship for Academic Merit
1989
Alpha Omega Alpha
1990
Franklin C. McLean Scholar National Medical Fellowships
1990
RESIDENCY
Administrative Chief Resident
1994-1995
Excellence in Teaching Award
1995
PROFESSIONAL
CREOG Resident Education Award
The Johns Hopkins Hospital
Department of Gynecology and Obstetrics
2002, 2004
Excellence in Resident Education & Mentoring
The Johns Hopkins Hospital
Department of Gynecology and Obstetrics
2005, 2007, 2009
Philip J. DiSaia Prestigious Chair in Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Irvine – Medical Center
2012
Associated Medical Students Golden Apple Award
University of California, Irvine – School of Medicine
2013, 2014
Annual Kirk A. Keegan Jr. Teaching Award
University of California, Irvine
Department of Obstetrics and Gynecology
2013, 2014
OTHER PROFESSIONAL RECOGNITION
Baltimore’s Top Doctors – Gynecologic Oncology
2002, 2006
Castle Connolly America’s Top Doctor
2009, 2010
Best Doctors in America
2009, 2010
US News and World Report – Top Doctor
2011 - 2013
Showmark America’s Top Physician for Cancer
2013, 2014
Appointments
CURRENT APPOINTMENT
Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Irvine - School of Medicine
2010 - present
PREVIOUS APPOINTMENTS
Professor
The Kelly Gynecologic Oncology Service
Department of Gynecology and Obstetrics
The Johns Hopkins University School of Medicine
2008 - 2010
Professor
Department of Oncology
The Johns Hopkins University School of Medicine
2008 - 2010
Associate Professor
The Kelly Gynecologic Oncology Service
Department of Gynecology and Obstetrics
The Johns Hopkins University School of Medicine
2003 - 2008
Associate Professor
Department of Oncology
The Johns Hopkins University School of Medicine
2003-2008
Assistant Professor
The Kelly Gynecologic Oncology Service
Department of Gynecology and Obstetrics
The Johns Hopkins University School of Medicine
1998 - 2003
Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Irvine - School of Medicine
2010 - present
PREVIOUS APPOINTMENTS
Professor
The Kelly Gynecologic Oncology Service
Department of Gynecology and Obstetrics
The Johns Hopkins University School of Medicine
2008 - 2010
Professor
Department of Oncology
The Johns Hopkins University School of Medicine
2008 - 2010
Associate Professor
The Kelly Gynecologic Oncology Service
Department of Gynecology and Obstetrics
The Johns Hopkins University School of Medicine
2003 - 2008
Associate Professor
Department of Oncology
The Johns Hopkins University School of Medicine
2003-2008
Assistant Professor
The Kelly Gynecologic Oncology Service
Department of Gynecology and Obstetrics
The Johns Hopkins University School of Medicine
1998 - 2003
Awards and Honors
The Golden Apple Award
Awarded to a clinical faculty member for outstanding teaching
School of Medicine
University of California, Irvine
2020
Excellence in Teaching Award
School of Medicine
University of California, Irvine
2016
Awarded to a clinical faculty member for outstanding teaching
School of Medicine
University of California, Irvine
2020
Excellence in Teaching Award
School of Medicine
University of California, Irvine
2016
Publications
PEER REVIEWED ARTICLES
1. Bristow RE and Karlan BY. The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol 1996; 8: 32-37.
2. Bristow RE and Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66: 499-507
3. Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection criteria and review of the literature. Cancer 1996; 78: 2049-2062.
4. Bristow RE, Baldwin RL, Korc M, Karlan BY: Altered expression of transforming growth factor beta ligands and receptors in primary and recurrent ovarian cancer. Cancer 1999; 85: 658-668.
5. del Carmen MG, Montz FJ, Bristow RE, Bovicelli A, Cornelison T, Trimble E. Ethnic differences in patterns of care of Stage IA(1) and Stage IA(2) cervical cancer. Gynecol Oncol 1999; 75: 113-117.
6. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72: 278-287.
7. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB Endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000; 78: 85-91.
8. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O’Neill MJ, Trimble EL, Montz FJ. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000; 89: 1532-1540.
9. Zerbe MJ, Bristow R, Grumbine FC, Montz FJ. Inability of pre-operative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporeal spread of endometrial cancer. Gynecol Oncol 2000; 78: 67-70.
10. Bovicelli A. Bristow RE, Montz FJ. HPV testing: Where are we now? Anticancer Research 2000; 20: 4673-4680.
11. Chin AB, Bristow RE, Korst LM, Walts A, Lagasse LD. The significance of atypical glandular cells on routine cervical cytology testing in a community based population. Amer J Obstet Gynecol 2000; 182: 1278-1282.
12. Nguyen C, Montz FJ, Bristow RE. Management of Stage I cervical cancer in Pregnancy. Obstet Gynecol Surv 2000; 55: 633-643.
13. Zerbe MJ, Zhang J, Bristow RE, Grumbine FC, Abularach S, Montz FJ. Retrograde seeding of malignant cells during hysteroscopy in presumed early endometrial cancer. Gynecol Oncol 2000; 79; 55-58.
14. Montz FJ, Farber F, Bristow RE, Cornelison T. Impact of increasing Papanicolaou test sensitivity and compliance: A modeled cost and outcomes analysis. Obstet Gynecol 2001; 97: 781-788.
15. Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81: 92-99.
16. Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of loco-regional (stage I-III) disease. Gynecol Oncol 2001; 81: 279-286.
17. Bristow RE, Smith Sehdev AE, Kaufman HS, Kurman RJ, Montz FJ. Ablation of metastatic ovarian carcinoma with the argon beam coagulator: Pathologic analysis of tumor destruction. Gynecol Oncol 2001; 83: 49-55.
18. Bristow RE and Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 2001: 83: 39-48.
19. Cornelison TL, Montz FJ, Bristow RE, Chou B, Bovicelli A, Trimble EL, Zeger SL. The impact of the 1990 changes in Medicare Pap smear payment guidelines on the Incidence of cervical cancer in Medicare eligible patients. Obstet Gynecol 2002; 100: 79-86.
20. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
21. Becker SO, Tomacruz RS, Kaufman HS, Bristow RE, Montz FJ. Management of rectal cancer in female patients: The women’s health perspective. J Am Coll Surg. 2002; 194: 315-323.
22. Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ. Positron Emission Tomography (PET) for Detecting Clinically Occult Surgically Resectable Metastatic Ovarian Carcinoma. Gynecol Oncol 2002; 85: 196-200.
23. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186: 651-647.
24. Pannu HK, Bristow RE, Montz FJ, Fishman EK. Dual phase multidetector computed tomography with volume display in gynecologic cancers. J Women’s Imaging 2002; 4: 73-79.
25. Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 2002; 86: 163-170.
26. Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Recurrent micropapillary serous ovarian carcinoma: the role of secondary cytoreductive surgery. Cancer 2002; 95: 791-800.
27. Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, Berek JS, Farias-Eisner R. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer 2002; 12: 454-458.
28. Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO Stage IIIC Endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 2003; 13: 664-672.
29. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak MZ, Fishman EK, Wahl RL, Montz FJ. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90: 519-528.
30. Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003; 197: 565-574.
31. Wang BG, Huang HY, Chen YC, Bristow RE, Cheng K, Roden R, Chen DW, Shih IM. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-3968.
32. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics 2003; 23: 687-701.
33. del Carmen MG, Smith-Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer 2003; 98: 1658-1663.
34. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 2004; 24: 209-223.
35. Gossett DR, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ. Inability of immunohistochemical markers to predict endometrial cancer recurrence. Int J Gynecol Cancer 2004; 14: 145-151.
36. Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET/CT detection of abdominal recurrence of ovarian cancer: radiologic – surgical correlation. Abdominal Imaging 2004; 39: 398-403.
37. Bristow RE, Zahurak ML, del Carmen MG, Gordon, Fox, HE, Trimble EL, Montz FJ. Ovarian Cancer Surgery in Maryland: Volume-Based Access to Care. Gynecologic Oncology 2004; 93: 353-360.
38. Wolfberg A, Montz FJ, Bristow RE. The role obesity in the surgical management of advanced stage ovarian cancer. J Reprod Med 2004; 49: 473-476.
39. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IM. Characterization of active mitogen-activated protein kinase in ovarian serous Carcinomas. Clin Cancer Res 2004; 10: 6432-6436.
40. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IM. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005; 65: 1994-2000.
41. Simpkins F, Zahurak M, Armstrong D, Grumbine F, Bristow R. Ovarian malignancy in breast cancer patients with an adnexal mass. Obstet Gynecol 2005; 105: 507-513.
42. Diaz-Montes TP, Alberg A, Zahurak ML, Trimble EL, Bristow RE. Cancer of Uterine corpus among Hispanic women living in the United States: patterns of staging, diagnosis, and primary treatment. Gynecol Oncol 2005; 96: 753-759.
43. Garg R, Zahurak ML, Trimble EL, Armstrong DK, Bristow RE. Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol 2005; 99: 65-70.
44. Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005; 99: 294-300.
45. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Gordon TA, Armstrong DK, Bristow RE. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol 2005; 99: 352-7.
46. Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol 2005; 99: 301-8.
47. Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci 2005; 102: 14004-9.
48. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, Bristow RE. Risk of epithelial ovarian cancer recurrence in patients with rising Serum CA-125 levels within the normal range. J Clin Oncol 2005; 23: 9338-43.
49. Diaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol 2005; 100: 139-144.
50. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98: 1-9.
51. Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, Trimble EL, Warren JL. Associations between hospital and surgeon procedures volumes and patient outcome after ovarian cancer resection. J Natl Cancer Inst 2006; 98: 163-171.
52. Bristow RE, Nugent AC, Zahurak ML, Khouzhami V, Fox HE. Impact of surgeon specialty on ovarian conserving surgery in young females with an adnexal mass. J Adolesc Health 2006; 39: 411-416.
53. Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL II, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol. 2006; 103: 201-287.
54. Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL II. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 2006 Nov; 103: 709-13.
55. Alphs HH, Zahurak ML, Bristow RE, Diaz-Montes TP. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol 2006 Dec; 103: 1048-53.
56. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Bristow RE. Uterine cancer in Maryland: Impact of surgeon case volume and other prognostic factors on short-term mortality. Gynecol Oncol 2006 Dec; 103: 1043-7.
57. Bristow RE, Chi DS. Neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 2006; 2006Dec; 103: 1070-6.
58. Diaz-Montes, TP, Farinola MA, Zahurak ML, Bristow RE, Rosenthal DL. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol 2006: 104: 366-371.
59. Karam AK, Santillan A, Bristow RE, Giuntoli RL II, Gardner GJ, Cass I, Karlan BY, Li AJ. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol 2006; 104: 377-380.
60. Nakayma K, Nakayma N, Davidson B, Sheu JJC, Santillan A, Salani R, Bristow RE, Morin PJ, Kurma RJ, Wang TL, Shi IM. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Nat Acad Sci 2006;103:18739-44.
61. Santillan A, Karam AK, Li AJ, Giuntoli RL II, Gardner GJ, Cass I, Karlan BY, Bristow RE. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2006: 104: 685-690.
62. Bristow RE, Eisenhauer E, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007; 104: 480-490.
63. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL II, Peeler ST. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol 2007; 104: 739-746.
64. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007; 109: 685-691.
65. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider C. Computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer: a multi-institutional reciprocal validation study. J Clin Oncol 2007; 25: 384-389.
66. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IM. Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol 2007; 26: 141-146.
67. Santillan A, Kim YW, Gardner GJ, Giuntoli RL II, Shih IM, Bristow RE. Differences of chemoresistance assay between invasive micropapillary low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 2007; 17: 601-606.
68. Armstrong DK, Bookman MA, McGuire WA, Bristow RE, Schilder JM. A phase I study of paclitaxel, topotecan, cisplatin, and filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2007: 105: 667-671.
69. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Meisner BC, Frick KD, Armstrong DK. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 2007: 109: 1513-1522.
70. Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of uterine leiomyosarcoma. Gynecol Oncol 2007; 106: 82-88.
71. McCormick, CC, Giuntoli RL 2nd, Gardner GJ, Schulick RD, Bristow RE. The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol 2007: 105: 791-795.
72. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IeM. Expression of extracellular matrix proteins in ovarian serous tumor. Int J Gynecol Pathol 2007; 26: 141-146.
73. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007; 31: 988-998.
74. Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Armstrong DK, Frick KD. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel for Stage III ovarian cancer: A cost-effectiveness analysis. Gynecol Oncol 2007; 106: 476-481.
75. Bazzaro M, Santillan A, Lin Z, Tang T, Lee MK, Bristow RE, Shi IM, Roden RB. Myosin II Co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol 2007; 171: 1640-1649.
76. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow RE, Chi DS, Cliby WA. A new frontier for quality of care in gynecologic oncology Surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007; 107: 99-106.
77. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Bristow RE. Concentration of uterine cancer surgical care among the elderly: a population-based perspective. Gynecol Oncol 2007; 107; 436-440.
78. Diaz-Montes TP, Zahurak ML, Bristow RE. Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer. Gynecol Oncol 2007; 107; 464-468.
79. Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol 2007; 107; 495-499.
80. Salani R, Diaz-Montes TP, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol 2007;14; 3552-3557.
81. Richman J, Rowlingson AJ, Maine DN, Courpas G, Bristow RE., Liu SS, Wu CL. The effects of epidural catheter location on outcomes in women undergoing gynecologic surgery with an abdominal incision: A randomized clinical trial. Acute Pain 2007; 9: 109-118.
82. Salani R, Kurman RJ, Giuntoli RL II, Gardner GJ, Bristow RE, Wang TL, Shih IM. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008; 18: 487-491.
83. Gerardi MA, Santillan A, Meisner B, Zahurak ML, Diaz-Montes TP, Giuntoli RL II, Bristow RE. A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers. Gynecol Oncol 2008:108; 282-286.
84. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008; 108: 271-5.
85. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S,
Cho KR, Copeland L, Eifel P, Huh WK, Jaggermauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR 3rd, Morgan M, Morgan RJ Jr, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W Jr, Teng N.Cervical cancer. J Natl Compr Canc Netw 2008; 6: 14-36.
86. Judson K, McCormick C, Vang R, Yemelyanova AV, Wu LS, Bristow RE, Ronnett BM. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement. Int J Gynecol Pathol 2008; 27: 182-190.
87. Bristow RE, Peiretti M, Zanagnolo V, Salani R, Giuntoli RL 2nd, Maggioni A. Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol 2008; 109: 364-369.
88. Santillan A, Govan L, Zahurak ML, Diaz-Montes TP, Giuntoli RL 2nd, Bristow RE. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice. Gynecol Oncol 2008; 109; 388-393.
89. Rybak EA, Polotsky AJ, Woreta T, Hailpern SM, Bristow RE. Explained compared With unexplained fever in postoperative myomectomy and hysterectomy patients. Obstet Gynecol 2008; 111: 1137-1142.
90. Helm CW, Bristow RE, Kusamura S, Baratto D, Deraco M. Hyperthermic
intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 2008; 98: 283-290.
91. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by Bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008; 15: 7340-7347.
92. Herzer KR, Rodriguez-Paz JM, Doyle PA, Flint PW, Feller-Kopman DJ, Herman J, Bristow RE, Cover R, Pronovost PJ, Mark LJ. A practical framework for patient care teams to prospectively identify and mitigate clinical hazards. Jt Comm J Qual Patient Saf. 2009; 35: 72-81.
93. Tanner EJ, Zahurak ML, Bristow RE, Diaz-Montes TP. Surgical care of young women diagnosed with ovarian cancer: a population-based perspective. Gynecol Oncol 2008; 111; 221-225.
94. Guile MW, Horne AL, Thompson SD, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE. Intraperitoneal chemotherapy for stage III ovarian cancer using the Gynecologic Oncology Group Protocol 172 IP regimen: impact of supportive care using Aprepitant and Pegfilgrastim on treatment completion rate. Clin Ovarian Cancer 2008; 1: 68-71.
95. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112: 265-274.
96. Salani R, Puri I, Bristow RE. Adenocarcinoma in situ of the uterine cervix: a meta-analysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol 2009; 200: 182.e1-5.
97. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR. Improved progression-free and Overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;; doi: 10.1016/j.ygyno.2009.03.018.
98. Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih IM, Roden RB. p53 autoantibodies, cytokine levels, and ovarian carcinogenesis. Gynecol Oncol 2009; Apr 25. [Epub ahead of print, PMID 19398128].
99. Tatsumi M, Cohade C, Bristow RE, Wahl RL. Imaging cervical cancer with FDG-PET/CT: direct comparison with PET. Mol Imaging Biol 2009; 11: 229-35.
100. Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda SM, Diaz-Montes TP, Giuntoli RL. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol 2009; 114: 173-177.
101. Barlin JN, Ueda SM, Bristow RE. Cytoreductive surgery for advanced and recurrentendometrial cancer: a review of the literature. Women’s Health 2009; 5: 403-411.
102. Barlin JN, Bristow RE, Bleich K, Giuntoli RL, Thompson S, Diaz-Montes TP. Computed tomography peritoneography prior to intraperitoneal chemotherapy in advanced mullerian cancer: a pilot study. Clin Imaging 2009; in press.
103. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian Cancer. BMC Cancer 2009; 9: 244
104. Bristow RE. Advanced cytoreductive surgery in gynecologic oncology. Gynecol Oncol 2009; 114 (2Suppl): S1-2.
105. Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009; 29: 2875-2884.
106. Salani R, Gerardi MA, Barlin JN, Veras E, Bristow RE. Surgical approaches and short-term surgical outcomes for patients with morbid obesity and endometrial cancer. J Gynecol Surg 2009; 25: 41-48.
107. Bristow RE, Puri I, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Analysis of contemporary trends in access to high-volume ovarian cancer surgical care. Ann Surg Oncol 2009; Aug 27 [Epub ahead of print] PMID: 19711131.
108. Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol 2009; Sept 17 [Epub ahead of print] PMID: 19766295.
109. Ueda SM, Mao TL, Kuhajda FP, Vassontara C, Giuntoli RL, Bristow RE, Kurman RJ, Shih IM. Trophoblastic neoplasms express fatty acid synthetase, which may be a therapeutic target via its inhibitor C93. Am J Pathol 2009; 175: 2618-2624.
110. Ibeanu OA, Bristow RE. Predicting the surgical outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer 2010; Suppl 1: S1-11.
111. Barlin J, Bristow RE, Murillo L, Zahurak ML, Veras E. Salani R. The predictive value of endocervical curettage at cervical conization, and provider practices in the management of high-grade cervical dysplasia. J Reprod Med 2009; in press.
112. Pant AC, Diaz-Montes T, Tanner E, Ahmad S, Giuntoli RL, Holloway RW, Bristow RE. Correlation of extreme drug resistance assay results and progression free survival following intraperitoneal chemotherapy for advanced ovarian cancer. J Chemotherapy 2010; 22: 270-274.
113. Pant AC, Santillan A, Diaz-Montes T, Giuntoli RL, Bristow RE. Splenectomy in cytoreductive surgery for advanced ovarian cancer and subsequent intraperitoneal chemotherapy. J Gynecol Surg 2010; 26: 179-182.
114. Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE. Surveillance for the detection of recurrent ovarian cancer: survival impact of lead Time bias? Gynecol Oncol 2010; 117: 336-340.
115. Barlin JN, Bristow RE, Bleich K, Giuntoli RL 2nd, Thompson S, Diaz-Montes TP. Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot study. Clin Imaging 2010; 34: 191-195.
116. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010: 118: 14-18.
117. Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wanf TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IM. Expression of fatty acid synthetase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol 2010; vol 2010, article ID 285191. doi: 10.1155/2010/185191.
118. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 2010; 118; 262 267.
119. Bashir S, Gerardi MA, Giuntoli RL, Montes TP, Bristow RE. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol Oncol 2010; 119: 255-258.
120. Aletti GD, Eisenhauer EL, SAntillan A, Axtell A, Aletii G, Holschneider C, Chi DS, Bristow RE, Cliby WA. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 2011; 120: 23-28.
121. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2011; 29: 69-75.
122. Gourin CG, Forastierre AA, Sanguineti G, Marur S, Koch WM, Bristow RE. Volume-based trends in laryngeal cancer surgery. Laryngoscope 2011; 121: 77-84.
123. Krill LS, Ueda SM, Gerardi M, Bristow RE. Analysis of postoperative Complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cances. Gynecol Oncol 2011; 120: 220-223.
124. Gourin CG, Tufano RP, Forastierre AA, Koch WM, Pawlik TM, Bristow RE. Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg 2010; 136: 1191-1198.
125. Gourin CG, Forastierre AA, Sanguineti G, Koch WM, Marur S, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of Laryngeal cancer surgical care. Laryngoscope 2011; 121: 85-90.
126. Bristow RE, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecolo Oncol 2011; 121: 364-368.
127. Fleury AC, Ibeanu OA, Bristow RE. Racial disparities in surgical care for uterine Cancer. Gynecol Oncol 2011; 121: 571-576.
128. Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE. Volume-based trends in surgical care of patients with oropharyngeal cancer. Laryngoscope 2011; 121: 738-745.
129. Eskander RN, Randall LM, Berman ML, Tewari KS, DiSaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011; 205: 103-110.
130. Gourin CG, Forastiere AA< Sanguineti G, Marur S, Koch WM, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of Oropharyngeal surgical care. Laryngoscope 2011; 121: 746-752.
131. Eskander RN, Bristow RE, Saenz NC, Saenz CC. A retrospective review of the effect of surgeon specialty on the management of 190 benign and malignant pediatric and adolescent adnexal masses. J Pediatr Adolesc Gynecol 2011l 24: 282-285.
132. Levinson KL, Bristow RE, Donohue PK, Kanarek NF, Trimble CL. Impact of payer status on treatment of cervical cancer at a tertiary referral center. Gynecol Oncol 2011; 122: 324-327.
133. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011; 122: 319-323.
134. Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjaer SK, Shih IeM, Roden RB. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 2011; 122: 560-566.
135. Giuntoli RL 2nd, Bristow RE, Diaz-Montes TP, Armstrong DK. Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer. J Chemother 2011; 23: 163-167.
136. Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, Goff BA. Post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204: 466-478.
137. Salani R, Nagel CI, Drennen E, Bristow RE. Recurrence patterns and surveillance for patients with early stage endometrial cancer. Gynecol Oncol 2011; 123: 205-207.
138. Gardner GJ, Baser RE, Brady MF, Bristow RE, Markman M, Spriggs D,
Thaler HT. CA215 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 2012; 124: 216-220.
139. Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, Bristow RE. Stage I noninvasive and minimally invasive uterine serous Carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Oncol 2012; 22: 273-279.
140. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-482.
141. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol 2012; 125: 483-492.
142. Chang SJ, Bristow RE, Ryu HS. A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer. Gynecol Oncol 2012; 126: 82-86.
143. Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer: a multi-center analysis of surgical and oncologic outcomes. Gynecol Oncol 2012; 126: 220-223.
144. Chang SJ, Bristow RE, Ryu HS. Prognostic significant of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecol Oncol 2012; 126: 381-386.
145. Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, Munroe DG. Ovarian malignancy risk stratification using a multivariate index assay. Gynecol Oncol 2012; 128: 252-259.
146. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012; 19: 4059-4067.
147. Tergas AI, Tseng JH, Bristow RE. Impact of race and ethnicity on treatment and survival of women with vulvar cancer in the United States. Gynecol Oncol 2013; 128: 154-158.
148. Chang SJ, Bristow RE, Ryu HS. Ananlysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. J Gynecol Oncolo 2013; 24: 29-36.
149. Al Rawhi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013; Feb 28:2: doi: 10.1002/14651858.
150. Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY, Mutch DG, Cliby WA. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 2013; 105: 823-832.
151. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among African-Americans in the United States. Gynecol Oncol 2013; 130: 652-659.
152. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013; 130: 493-498.
153. Bristow RE, Chang J, Ziogas A, Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 2013; 121: 1226-1234.
154. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, Tewari KS, Munroe DG, Ueland FR. Impact of a multivariate index assay on referral patterns For surgical management of an adnexal mass. Am J Obstet Gynecol 2013; 209: 581e1-8.
155. Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, Gershenson DM, Gynecologic Oncology Group. Survival in women with grade 1 serous ovarian Carcinoma. Obstet Gynecol 2013; 122: 225-232.
156. Liu FW, Randall LM, Tewari KS, Bristow RE. Racial disparities and patterns of ovarian cancer surgical care in California. Gynecol Oncol 2013; doi: 10.1016/j.ygyno.2013.08.035
157. Longoria TC, Ueland FR, Zhang Z, Chan DW, Smith A, Fung ET, Munroe DG, Bristow RE. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. Am J Obstet Gynecol 2014; 210: 78e1-9.
158. Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow RE, Diaz-Montes TP, Palermo R, Kurman RJ. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol 2013; doi: 10.1016/j.ygyno.2013.11.033. PMID: 24316307.
159. Fader AN, Java J, Krivak TC, Bristow RE, Tergas AI, Bookman MA, Armstrong DK, Tanner EJ, Gershenson DM. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013; doi: 10.1016/jygyno.2013.11.016. PMID: 24333362.
160. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 2013; doi: 10.1016/j.ygyno.2013.12.017. PMID: 24361578
161. Goodrich ST, Bristow RE, Santoso JT, Miller RW, Smith A, Zhang Z, Ueland FR. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. Am J Obstet Gynecol 2014; 211: 65.e1-11. PMID 24530816.
162. Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 2014; 134: 60-67. PMID: 24680770.
163. Hodeib M, Eskander RN, Bristow RE. New paradigms in the surgical and adjuvant treatment of ovarian cancer. Minerva Ginecol 2014; 66: 179-192. PMID: 24848076.
164. Krill LS, Adelson JW, Randall LM, Bristow RE. Clinical commentary: medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using non-bevacizumab containing arm feasible in patients with recurrent cervical cancer. Gynecol Oncol 2014; 134: 447-449. PMID: 24976631.
165. Eskander RN, Chang J, Ziogas A, Anton-Culver H, Bristow RE. Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a Medicare population. J Clin Oncol 2014; 32: 4113-4119. PMID: 25385738.
166. Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socio-economic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol 2015; 212:468.e1-9. PMID: 25448522.
167. Cliby WA, Powell MA, Al-Hammadi N, Chen L, Philip Miller J, Roland PY, Mutch DG, Bristow RE. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol 2015; 136: 11-17. PMID: 254493311.
168. Liu FW, Galvan-Turner VB, Pfaendler KS, Longoria TC, Bristow RE. A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. Am J Obstet Gynecol 2015; 212(6): 717-724. PMID: 25582101.
169. Bristow RE, Chang J, Ziogas A, Gillen DL, Bai L, Vieira VM. Spatial analysis of advanced-stage ovarian cancer mortality in California. Am J Obstet Gynecol 2015; 213(1): 43.e1-8. PMID: 25644440.
170. Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol 2015; 125: 833-842. PMID: 25751200.
171. Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Impact of National Cancer Institute Comprehensive Cancer Center on ovarian cancer treatment and survival. J Am Coll Surg 2015; 220: 940-950. PMID: 25840536.
172. Forde GK, Chang J, Ziogas A, Tewari K, Bristow RE. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population. Gynecol Oncol 2015; 137: 479-484. PMID: 25866323.
173. Chang SJ, Bristow RE. Surgical technique of en bloc pelvic resection for advanced ovarian cancer. J Gynecol Oncol 2015; 26; 155. PMID: 25872895.
174. Hodeib M, Chang J, Liu F, Ziogas A, Dilley S, Randall LM, Anton-Culver H. Bristow RE. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecol Oncol 2015; 138: 121-127. PMID: 25913132.
175. Tseng JH, Long Roche K, Jernigan AM, Salani R, Bristow RE, Fader AN. Lifestyle and weight management counseling in uterine cancer survivors: a study of the Uterine Cancer Action Network. Int J Gynecol Cancer 2015; PMID 25966932.
176. LaFargue CJ, Bristow RE. Transdiaphragmatic cardiophrenic lymph node resection for stage IV ovarian cancer. Gynecol Oncol 2015; doi: 10.1016/j.ygyno.2015.06.002. PMID 26049122.
177. Dottino JA, Cliby WA, Myers ER, Bristow RE, Havrilesky LJ. Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention. Gynecol Oncol 2015;. Doi: 10.1016/j.ygyno.2015.06.013. PMID: 26072441
178. Cohn DE, Havrilesky LJ, Lipscomb J, Hsieh S, Walker JL, Wright AA, Alvarez RD, Karlan BY, Bristow RE, DiSilvestro PA, Wakabayashi MT, Morgan R, Mukamel DB, Wenzel L. Consensus in controversy: the modified Delphi method applied to gynecologic oncology practice. Gynecol Oncol 2015; doi: 101.10116/j.gyno.2015.07.014. PMID: 26177553.
1. Bristow RE and Karlan BY. The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol 1996; 8: 32-37.
2. Bristow RE and Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66: 499-507
3. Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection criteria and review of the literature. Cancer 1996; 78: 2049-2062.
4. Bristow RE, Baldwin RL, Korc M, Karlan BY: Altered expression of transforming growth factor beta ligands and receptors in primary and recurrent ovarian cancer. Cancer 1999; 85: 658-668.
5. del Carmen MG, Montz FJ, Bristow RE, Bovicelli A, Cornelison T, Trimble E. Ethnic differences in patterns of care of Stage IA(1) and Stage IA(2) cervical cancer. Gynecol Oncol 1999; 75: 113-117.
6. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72: 278-287.
7. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB Endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000; 78: 85-91.
8. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O’Neill MJ, Trimble EL, Montz FJ. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000; 89: 1532-1540.
9. Zerbe MJ, Bristow R, Grumbine FC, Montz FJ. Inability of pre-operative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporeal spread of endometrial cancer. Gynecol Oncol 2000; 78: 67-70.
10. Bovicelli A. Bristow RE, Montz FJ. HPV testing: Where are we now? Anticancer Research 2000; 20: 4673-4680.
11. Chin AB, Bristow RE, Korst LM, Walts A, Lagasse LD. The significance of atypical glandular cells on routine cervical cytology testing in a community based population. Amer J Obstet Gynecol 2000; 182: 1278-1282.
12. Nguyen C, Montz FJ, Bristow RE. Management of Stage I cervical cancer in Pregnancy. Obstet Gynecol Surv 2000; 55: 633-643.
13. Zerbe MJ, Zhang J, Bristow RE, Grumbine FC, Abularach S, Montz FJ. Retrograde seeding of malignant cells during hysteroscopy in presumed early endometrial cancer. Gynecol Oncol 2000; 79; 55-58.
14. Montz FJ, Farber F, Bristow RE, Cornelison T. Impact of increasing Papanicolaou test sensitivity and compliance: A modeled cost and outcomes analysis. Obstet Gynecol 2001; 97: 781-788.
15. Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81: 92-99.
16. Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of loco-regional (stage I-III) disease. Gynecol Oncol 2001; 81: 279-286.
17. Bristow RE, Smith Sehdev AE, Kaufman HS, Kurman RJ, Montz FJ. Ablation of metastatic ovarian carcinoma with the argon beam coagulator: Pathologic analysis of tumor destruction. Gynecol Oncol 2001; 83: 49-55.
18. Bristow RE and Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 2001: 83: 39-48.
19. Cornelison TL, Montz FJ, Bristow RE, Chou B, Bovicelli A, Trimble EL, Zeger SL. The impact of the 1990 changes in Medicare Pap smear payment guidelines on the Incidence of cervical cancer in Medicare eligible patients. Obstet Gynecol 2002; 100: 79-86.
20. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
21. Becker SO, Tomacruz RS, Kaufman HS, Bristow RE, Montz FJ. Management of rectal cancer in female patients: The women’s health perspective. J Am Coll Surg. 2002; 194: 315-323.
22. Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ. Positron Emission Tomography (PET) for Detecting Clinically Occult Surgically Resectable Metastatic Ovarian Carcinoma. Gynecol Oncol 2002; 85: 196-200.
23. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186: 651-647.
24. Pannu HK, Bristow RE, Montz FJ, Fishman EK. Dual phase multidetector computed tomography with volume display in gynecologic cancers. J Women’s Imaging 2002; 4: 73-79.
25. Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 2002; 86: 163-170.
26. Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Recurrent micropapillary serous ovarian carcinoma: the role of secondary cytoreductive surgery. Cancer 2002; 95: 791-800.
27. Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, Berek JS, Farias-Eisner R. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer 2002; 12: 454-458.
28. Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO Stage IIIC Endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 2003; 13: 664-672.
29. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak MZ, Fishman EK, Wahl RL, Montz FJ. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90: 519-528.
30. Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003; 197: 565-574.
31. Wang BG, Huang HY, Chen YC, Bristow RE, Cheng K, Roden R, Chen DW, Shih IM. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-3968.
32. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics 2003; 23: 687-701.
33. del Carmen MG, Smith-Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer 2003; 98: 1658-1663.
34. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 2004; 24: 209-223.
35. Gossett DR, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ. Inability of immunohistochemical markers to predict endometrial cancer recurrence. Int J Gynecol Cancer 2004; 14: 145-151.
36. Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET/CT detection of abdominal recurrence of ovarian cancer: radiologic – surgical correlation. Abdominal Imaging 2004; 39: 398-403.
37. Bristow RE, Zahurak ML, del Carmen MG, Gordon, Fox, HE, Trimble EL, Montz FJ. Ovarian Cancer Surgery in Maryland: Volume-Based Access to Care. Gynecologic Oncology 2004; 93: 353-360.
38. Wolfberg A, Montz FJ, Bristow RE. The role obesity in the surgical management of advanced stage ovarian cancer. J Reprod Med 2004; 49: 473-476.
39. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IM. Characterization of active mitogen-activated protein kinase in ovarian serous Carcinomas. Clin Cancer Res 2004; 10: 6432-6436.
40. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IM. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005; 65: 1994-2000.
41. Simpkins F, Zahurak M, Armstrong D, Grumbine F, Bristow R. Ovarian malignancy in breast cancer patients with an adnexal mass. Obstet Gynecol 2005; 105: 507-513.
42. Diaz-Montes TP, Alberg A, Zahurak ML, Trimble EL, Bristow RE. Cancer of Uterine corpus among Hispanic women living in the United States: patterns of staging, diagnosis, and primary treatment. Gynecol Oncol 2005; 96: 753-759.
43. Garg R, Zahurak ML, Trimble EL, Armstrong DK, Bristow RE. Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol 2005; 99: 65-70.
44. Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005; 99: 294-300.
45. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Gordon TA, Armstrong DK, Bristow RE. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol 2005; 99: 352-7.
46. Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol 2005; 99: 301-8.
47. Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci 2005; 102: 14004-9.
48. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, Bristow RE. Risk of epithelial ovarian cancer recurrence in patients with rising Serum CA-125 levels within the normal range. J Clin Oncol 2005; 23: 9338-43.
49. Diaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol 2005; 100: 139-144.
50. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98: 1-9.
51. Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, Trimble EL, Warren JL. Associations between hospital and surgeon procedures volumes and patient outcome after ovarian cancer resection. J Natl Cancer Inst 2006; 98: 163-171.
52. Bristow RE, Nugent AC, Zahurak ML, Khouzhami V, Fox HE. Impact of surgeon specialty on ovarian conserving surgery in young females with an adnexal mass. J Adolesc Health 2006; 39: 411-416.
53. Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL II, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol. 2006; 103: 201-287.
54. Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL II. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 2006 Nov; 103: 709-13.
55. Alphs HH, Zahurak ML, Bristow RE, Diaz-Montes TP. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol 2006 Dec; 103: 1048-53.
56. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Bristow RE. Uterine cancer in Maryland: Impact of surgeon case volume and other prognostic factors on short-term mortality. Gynecol Oncol 2006 Dec; 103: 1043-7.
57. Bristow RE, Chi DS. Neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 2006; 2006Dec; 103: 1070-6.
58. Diaz-Montes, TP, Farinola MA, Zahurak ML, Bristow RE, Rosenthal DL. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol 2006: 104: 366-371.
59. Karam AK, Santillan A, Bristow RE, Giuntoli RL II, Gardner GJ, Cass I, Karlan BY, Li AJ. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol 2006; 104: 377-380.
60. Nakayma K, Nakayma N, Davidson B, Sheu JJC, Santillan A, Salani R, Bristow RE, Morin PJ, Kurma RJ, Wang TL, Shi IM. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Nat Acad Sci 2006;103:18739-44.
61. Santillan A, Karam AK, Li AJ, Giuntoli RL II, Gardner GJ, Cass I, Karlan BY, Bristow RE. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2006: 104: 685-690.
62. Bristow RE, Eisenhauer E, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007; 104: 480-490.
63. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL II, Peeler ST. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol 2007; 104: 739-746.
64. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007; 109: 685-691.
65. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider C. Computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer: a multi-institutional reciprocal validation study. J Clin Oncol 2007; 25: 384-389.
66. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IM. Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol 2007; 26: 141-146.
67. Santillan A, Kim YW, Gardner GJ, Giuntoli RL II, Shih IM, Bristow RE. Differences of chemoresistance assay between invasive micropapillary low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 2007; 17: 601-606.
68. Armstrong DK, Bookman MA, McGuire WA, Bristow RE, Schilder JM. A phase I study of paclitaxel, topotecan, cisplatin, and filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2007: 105: 667-671.
69. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Meisner BC, Frick KD, Armstrong DK. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 2007: 109: 1513-1522.
70. Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of uterine leiomyosarcoma. Gynecol Oncol 2007; 106: 82-88.
71. McCormick, CC, Giuntoli RL 2nd, Gardner GJ, Schulick RD, Bristow RE. The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol 2007: 105: 791-795.
72. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IeM. Expression of extracellular matrix proteins in ovarian serous tumor. Int J Gynecol Pathol 2007; 26: 141-146.
73. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007; 31: 988-998.
74. Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Armstrong DK, Frick KD. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel for Stage III ovarian cancer: A cost-effectiveness analysis. Gynecol Oncol 2007; 106: 476-481.
75. Bazzaro M, Santillan A, Lin Z, Tang T, Lee MK, Bristow RE, Shi IM, Roden RB. Myosin II Co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol 2007; 171: 1640-1649.
76. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow RE, Chi DS, Cliby WA. A new frontier for quality of care in gynecologic oncology Surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007; 107: 99-106.
77. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Bristow RE. Concentration of uterine cancer surgical care among the elderly: a population-based perspective. Gynecol Oncol 2007; 107; 436-440.
78. Diaz-Montes TP, Zahurak ML, Bristow RE. Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer. Gynecol Oncol 2007; 107; 464-468.
79. Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol 2007; 107; 495-499.
80. Salani R, Diaz-Montes TP, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol 2007;14; 3552-3557.
81. Richman J, Rowlingson AJ, Maine DN, Courpas G, Bristow RE., Liu SS, Wu CL. The effects of epidural catheter location on outcomes in women undergoing gynecologic surgery with an abdominal incision: A randomized clinical trial. Acute Pain 2007; 9: 109-118.
82. Salani R, Kurman RJ, Giuntoli RL II, Gardner GJ, Bristow RE, Wang TL, Shih IM. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008; 18: 487-491.
83. Gerardi MA, Santillan A, Meisner B, Zahurak ML, Diaz-Montes TP, Giuntoli RL II, Bristow RE. A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers. Gynecol Oncol 2008:108; 282-286.
84. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008; 108: 271-5.
85. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S,
Cho KR, Copeland L, Eifel P, Huh WK, Jaggermauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR 3rd, Morgan M, Morgan RJ Jr, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W Jr, Teng N.Cervical cancer. J Natl Compr Canc Netw 2008; 6: 14-36.
86. Judson K, McCormick C, Vang R, Yemelyanova AV, Wu LS, Bristow RE, Ronnett BM. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement. Int J Gynecol Pathol 2008; 27: 182-190.
87. Bristow RE, Peiretti M, Zanagnolo V, Salani R, Giuntoli RL 2nd, Maggioni A. Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol 2008; 109: 364-369.
88. Santillan A, Govan L, Zahurak ML, Diaz-Montes TP, Giuntoli RL 2nd, Bristow RE. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice. Gynecol Oncol 2008; 109; 388-393.
89. Rybak EA, Polotsky AJ, Woreta T, Hailpern SM, Bristow RE. Explained compared With unexplained fever in postoperative myomectomy and hysterectomy patients. Obstet Gynecol 2008; 111: 1137-1142.
90. Helm CW, Bristow RE, Kusamura S, Baratto D, Deraco M. Hyperthermic
intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 2008; 98: 283-290.
91. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by Bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008; 15: 7340-7347.
92. Herzer KR, Rodriguez-Paz JM, Doyle PA, Flint PW, Feller-Kopman DJ, Herman J, Bristow RE, Cover R, Pronovost PJ, Mark LJ. A practical framework for patient care teams to prospectively identify and mitigate clinical hazards. Jt Comm J Qual Patient Saf. 2009; 35: 72-81.
93. Tanner EJ, Zahurak ML, Bristow RE, Diaz-Montes TP. Surgical care of young women diagnosed with ovarian cancer: a population-based perspective. Gynecol Oncol 2008; 111; 221-225.
94. Guile MW, Horne AL, Thompson SD, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE. Intraperitoneal chemotherapy for stage III ovarian cancer using the Gynecologic Oncology Group Protocol 172 IP regimen: impact of supportive care using Aprepitant and Pegfilgrastim on treatment completion rate. Clin Ovarian Cancer 2008; 1: 68-71.
95. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112: 265-274.
96. Salani R, Puri I, Bristow RE. Adenocarcinoma in situ of the uterine cervix: a meta-analysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol 2009; 200: 182.e1-5.
97. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR. Improved progression-free and Overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;; doi: 10.1016/j.ygyno.2009.03.018.
98. Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih IM, Roden RB. p53 autoantibodies, cytokine levels, and ovarian carcinogenesis. Gynecol Oncol 2009; Apr 25. [Epub ahead of print, PMID 19398128].
99. Tatsumi M, Cohade C, Bristow RE, Wahl RL. Imaging cervical cancer with FDG-PET/CT: direct comparison with PET. Mol Imaging Biol 2009; 11: 229-35.
100. Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda SM, Diaz-Montes TP, Giuntoli RL. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol 2009; 114: 173-177.
101. Barlin JN, Ueda SM, Bristow RE. Cytoreductive surgery for advanced and recurrentendometrial cancer: a review of the literature. Women’s Health 2009; 5: 403-411.
102. Barlin JN, Bristow RE, Bleich K, Giuntoli RL, Thompson S, Diaz-Montes TP. Computed tomography peritoneography prior to intraperitoneal chemotherapy in advanced mullerian cancer: a pilot study. Clin Imaging 2009; in press.
103. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian Cancer. BMC Cancer 2009; 9: 244
104. Bristow RE. Advanced cytoreductive surgery in gynecologic oncology. Gynecol Oncol 2009; 114 (2Suppl): S1-2.
105. Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009; 29: 2875-2884.
106. Salani R, Gerardi MA, Barlin JN, Veras E, Bristow RE. Surgical approaches and short-term surgical outcomes for patients with morbid obesity and endometrial cancer. J Gynecol Surg 2009; 25: 41-48.
107. Bristow RE, Puri I, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Analysis of contemporary trends in access to high-volume ovarian cancer surgical care. Ann Surg Oncol 2009; Aug 27 [Epub ahead of print] PMID: 19711131.
108. Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol 2009; Sept 17 [Epub ahead of print] PMID: 19766295.
109. Ueda SM, Mao TL, Kuhajda FP, Vassontara C, Giuntoli RL, Bristow RE, Kurman RJ, Shih IM. Trophoblastic neoplasms express fatty acid synthetase, which may be a therapeutic target via its inhibitor C93. Am J Pathol 2009; 175: 2618-2624.
110. Ibeanu OA, Bristow RE. Predicting the surgical outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer 2010; Suppl 1: S1-11.
111. Barlin J, Bristow RE, Murillo L, Zahurak ML, Veras E. Salani R. The predictive value of endocervical curettage at cervical conization, and provider practices in the management of high-grade cervical dysplasia. J Reprod Med 2009; in press.
112. Pant AC, Diaz-Montes T, Tanner E, Ahmad S, Giuntoli RL, Holloway RW, Bristow RE. Correlation of extreme drug resistance assay results and progression free survival following intraperitoneal chemotherapy for advanced ovarian cancer. J Chemotherapy 2010; 22: 270-274.
113. Pant AC, Santillan A, Diaz-Montes T, Giuntoli RL, Bristow RE. Splenectomy in cytoreductive surgery for advanced ovarian cancer and subsequent intraperitoneal chemotherapy. J Gynecol Surg 2010; 26: 179-182.
114. Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE. Surveillance for the detection of recurrent ovarian cancer: survival impact of lead Time bias? Gynecol Oncol 2010; 117: 336-340.
115. Barlin JN, Bristow RE, Bleich K, Giuntoli RL 2nd, Thompson S, Diaz-Montes TP. Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot study. Clin Imaging 2010; 34: 191-195.
116. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010: 118: 14-18.
117. Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wanf TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IM. Expression of fatty acid synthetase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol 2010; vol 2010, article ID 285191. doi: 10.1155/2010/185191.
118. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 2010; 118; 262 267.
119. Bashir S, Gerardi MA, Giuntoli RL, Montes TP, Bristow RE. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol Oncol 2010; 119: 255-258.
120. Aletti GD, Eisenhauer EL, SAntillan A, Axtell A, Aletii G, Holschneider C, Chi DS, Bristow RE, Cliby WA. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 2011; 120: 23-28.
121. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2011; 29: 69-75.
122. Gourin CG, Forastierre AA, Sanguineti G, Marur S, Koch WM, Bristow RE. Volume-based trends in laryngeal cancer surgery. Laryngoscope 2011; 121: 77-84.
123. Krill LS, Ueda SM, Gerardi M, Bristow RE. Analysis of postoperative Complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cances. Gynecol Oncol 2011; 120: 220-223.
124. Gourin CG, Tufano RP, Forastierre AA, Koch WM, Pawlik TM, Bristow RE. Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg 2010; 136: 1191-1198.
125. Gourin CG, Forastierre AA, Sanguineti G, Koch WM, Marur S, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of Laryngeal cancer surgical care. Laryngoscope 2011; 121: 85-90.
126. Bristow RE, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecolo Oncol 2011; 121: 364-368.
127. Fleury AC, Ibeanu OA, Bristow RE. Racial disparities in surgical care for uterine Cancer. Gynecol Oncol 2011; 121: 571-576.
128. Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE. Volume-based trends in surgical care of patients with oropharyngeal cancer. Laryngoscope 2011; 121: 738-745.
129. Eskander RN, Randall LM, Berman ML, Tewari KS, DiSaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011; 205: 103-110.
130. Gourin CG, Forastiere AA< Sanguineti G, Marur S, Koch WM, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of Oropharyngeal surgical care. Laryngoscope 2011; 121: 746-752.
131. Eskander RN, Bristow RE, Saenz NC, Saenz CC. A retrospective review of the effect of surgeon specialty on the management of 190 benign and malignant pediatric and adolescent adnexal masses. J Pediatr Adolesc Gynecol 2011l 24: 282-285.
132. Levinson KL, Bristow RE, Donohue PK, Kanarek NF, Trimble CL. Impact of payer status on treatment of cervical cancer at a tertiary referral center. Gynecol Oncol 2011; 122: 324-327.
133. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011; 122: 319-323.
134. Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjaer SK, Shih IeM, Roden RB. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 2011; 122: 560-566.
135. Giuntoli RL 2nd, Bristow RE, Diaz-Montes TP, Armstrong DK. Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer. J Chemother 2011; 23: 163-167.
136. Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, Goff BA. Post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204: 466-478.
137. Salani R, Nagel CI, Drennen E, Bristow RE. Recurrence patterns and surveillance for patients with early stage endometrial cancer. Gynecol Oncol 2011; 123: 205-207.
138. Gardner GJ, Baser RE, Brady MF, Bristow RE, Markman M, Spriggs D,
Thaler HT. CA215 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 2012; 124: 216-220.
139. Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, Bristow RE. Stage I noninvasive and minimally invasive uterine serous Carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Oncol 2012; 22: 273-279.
140. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-482.
141. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol 2012; 125: 483-492.
142. Chang SJ, Bristow RE, Ryu HS. A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer. Gynecol Oncol 2012; 126: 82-86.
143. Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer: a multi-center analysis of surgical and oncologic outcomes. Gynecol Oncol 2012; 126: 220-223.
144. Chang SJ, Bristow RE, Ryu HS. Prognostic significant of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecol Oncol 2012; 126: 381-386.
145. Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, Munroe DG. Ovarian malignancy risk stratification using a multivariate index assay. Gynecol Oncol 2012; 128: 252-259.
146. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012; 19: 4059-4067.
147. Tergas AI, Tseng JH, Bristow RE. Impact of race and ethnicity on treatment and survival of women with vulvar cancer in the United States. Gynecol Oncol 2013; 128: 154-158.
148. Chang SJ, Bristow RE, Ryu HS. Ananlysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. J Gynecol Oncolo 2013; 24: 29-36.
149. Al Rawhi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013; Feb 28:2: doi: 10.1002/14651858.
150. Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY, Mutch DG, Cliby WA. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 2013; 105: 823-832.
151. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among African-Americans in the United States. Gynecol Oncol 2013; 130: 652-659.
152. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013; 130: 493-498.
153. Bristow RE, Chang J, Ziogas A, Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 2013; 121: 1226-1234.
154. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, Tewari KS, Munroe DG, Ueland FR. Impact of a multivariate index assay on referral patterns For surgical management of an adnexal mass. Am J Obstet Gynecol 2013; 209: 581e1-8.
155. Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, Gershenson DM, Gynecologic Oncology Group. Survival in women with grade 1 serous ovarian Carcinoma. Obstet Gynecol 2013; 122: 225-232.
156. Liu FW, Randall LM, Tewari KS, Bristow RE. Racial disparities and patterns of ovarian cancer surgical care in California. Gynecol Oncol 2013; doi: 10.1016/j.ygyno.2013.08.035
157. Longoria TC, Ueland FR, Zhang Z, Chan DW, Smith A, Fung ET, Munroe DG, Bristow RE. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. Am J Obstet Gynecol 2014; 210: 78e1-9.
158. Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow RE, Diaz-Montes TP, Palermo R, Kurman RJ. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol 2013; doi: 10.1016/j.ygyno.2013.11.033. PMID: 24316307.
159. Fader AN, Java J, Krivak TC, Bristow RE, Tergas AI, Bookman MA, Armstrong DK, Tanner EJ, Gershenson DM. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013; doi: 10.1016/jygyno.2013.11.016. PMID: 24333362.
160. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 2013; doi: 10.1016/j.ygyno.2013.12.017. PMID: 24361578
161. Goodrich ST, Bristow RE, Santoso JT, Miller RW, Smith A, Zhang Z, Ueland FR. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. Am J Obstet Gynecol 2014; 211: 65.e1-11. PMID 24530816.
162. Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 2014; 134: 60-67. PMID: 24680770.
163. Hodeib M, Eskander RN, Bristow RE. New paradigms in the surgical and adjuvant treatment of ovarian cancer. Minerva Ginecol 2014; 66: 179-192. PMID: 24848076.
164. Krill LS, Adelson JW, Randall LM, Bristow RE. Clinical commentary: medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using non-bevacizumab containing arm feasible in patients with recurrent cervical cancer. Gynecol Oncol 2014; 134: 447-449. PMID: 24976631.
165. Eskander RN, Chang J, Ziogas A, Anton-Culver H, Bristow RE. Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a Medicare population. J Clin Oncol 2014; 32: 4113-4119. PMID: 25385738.
166. Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socio-economic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol 2015; 212:468.e1-9. PMID: 25448522.
167. Cliby WA, Powell MA, Al-Hammadi N, Chen L, Philip Miller J, Roland PY, Mutch DG, Bristow RE. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol 2015; 136: 11-17. PMID: 254493311.
168. Liu FW, Galvan-Turner VB, Pfaendler KS, Longoria TC, Bristow RE. A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. Am J Obstet Gynecol 2015; 212(6): 717-724. PMID: 25582101.
169. Bristow RE, Chang J, Ziogas A, Gillen DL, Bai L, Vieira VM. Spatial analysis of advanced-stage ovarian cancer mortality in California. Am J Obstet Gynecol 2015; 213(1): 43.e1-8. PMID: 25644440.
170. Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol 2015; 125: 833-842. PMID: 25751200.
171. Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Impact of National Cancer Institute Comprehensive Cancer Center on ovarian cancer treatment and survival. J Am Coll Surg 2015; 220: 940-950. PMID: 25840536.
172. Forde GK, Chang J, Ziogas A, Tewari K, Bristow RE. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population. Gynecol Oncol 2015; 137: 479-484. PMID: 25866323.
173. Chang SJ, Bristow RE. Surgical technique of en bloc pelvic resection for advanced ovarian cancer. J Gynecol Oncol 2015; 26; 155. PMID: 25872895.
174. Hodeib M, Chang J, Liu F, Ziogas A, Dilley S, Randall LM, Anton-Culver H. Bristow RE. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecol Oncol 2015; 138: 121-127. PMID: 25913132.
175. Tseng JH, Long Roche K, Jernigan AM, Salani R, Bristow RE, Fader AN. Lifestyle and weight management counseling in uterine cancer survivors: a study of the Uterine Cancer Action Network. Int J Gynecol Cancer 2015; PMID 25966932.
176. LaFargue CJ, Bristow RE. Transdiaphragmatic cardiophrenic lymph node resection for stage IV ovarian cancer. Gynecol Oncol 2015; doi: 10.1016/j.ygyno.2015.06.002. PMID 26049122.
177. Dottino JA, Cliby WA, Myers ER, Bristow RE, Havrilesky LJ. Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention. Gynecol Oncol 2015;. Doi: 10.1016/j.ygyno.2015.06.013. PMID: 26072441
178. Cohn DE, Havrilesky LJ, Lipscomb J, Hsieh S, Walker JL, Wright AA, Alvarez RD, Karlan BY, Bristow RE, DiSilvestro PA, Wakabayashi MT, Morgan R, Mukamel DB, Wenzel L. Consensus in controversy: the modified Delphi method applied to gynecologic oncology practice. Gynecol Oncol 2015; doi: 101.10116/j.gyno.2015.07.014. PMID: 26177553.
NON-PEER REVIEWED ARTICLES
BOOKS, TEXTBOOKS
1. A Guide to Survivorship for Women with Ovarian Cancer. Montz F. J. and Bristow RE. 2005. Johns Hopkins University Press, Baltimore, MD.
2. Surgery for Ovarian Cancer: Principles and Practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
3. Early Diagnosis and Treatment of Cancer: Ovarian Cancer. Bristow RE and Armstrong DK eds. 2009. Elsevier, Philadelphia, PA.
4. Patients’ Guide to Ovarian Cancer. Salani R and Bristow RE. 2009. The Johns Hopkins University Press, Baltimore, MD
5. Surgery for Ovarian Cancer: Principles and Practice. 2nd Edition. Bristow RE, Karlan BY, Chi DS eds 2010. Informa Healthcare, New York, NY.
6. Gynecologic Oncology: Clinical Practice and Surgical Atlas. Karlan BY, Bristow RE, Li AJ eds. 2012 McGraw-Hill. New York, NY.
7. Radical and Reconstructive Gynecologic Cancer Surgery. Bristow RE and Chi DS eds. In press, McGraw-Hill. New York, NY.
BOOKS, TEXTBOOKS
1. A Guide to Survivorship for Women with Ovarian Cancer. Montz F. J. and Bristow RE. 2005. Johns Hopkins University Press, Baltimore, MD.
2. Surgery for Ovarian Cancer: Principles and Practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
3. Early Diagnosis and Treatment of Cancer: Ovarian Cancer. Bristow RE and Armstrong DK eds. 2009. Elsevier, Philadelphia, PA.
4. Patients’ Guide to Ovarian Cancer. Salani R and Bristow RE. 2009. The Johns Hopkins University Press, Baltimore, MD
5. Surgery for Ovarian Cancer: Principles and Practice. 2nd Edition. Bristow RE, Karlan BY, Chi DS eds 2010. Informa Healthcare, New York, NY.
6. Gynecologic Oncology: Clinical Practice and Surgical Atlas. Karlan BY, Bristow RE, Li AJ eds. 2012 McGraw-Hill. New York, NY.
7. Radical and Reconstructive Gynecologic Cancer Surgery. Bristow RE and Chi DS eds. In press, McGraw-Hill. New York, NY.
BOOK CHAPTERS, MONOGRAPHS
1. Baldwin RL, Yamada SD, Bristow RE, Chen L, Karlan BY. Ovarian epithelial growth regulation. In Ovarian cancer 5, Sharp F, Blackett, Berek J, and Bast R (eds). Isis Medical Media, Oxford 1998: 99-107.
2. Bristow RE and Steren A: Cervical cancer. In The Johns Hopkins Handbook of Gynecology and Obstetrics. Lambrou NC, Morse AN, Wallach EE (eds). pp339-363. 1999. Lippincott, Williams and Wilkins, Phildelphia.
3. Bristow RE and Karlan BY. Disorders of the uterine cervix. In Danforth’s Obstetrics and Gynecology, eighth edition. Scott JR, DiSaia PJ, Hammond CB, Spellacy WN (eds). pp 805-836. 1999. JB Lippincott Company, Philadelphia.
4. Bristow RE and Montz FJ. Cervical cancer in pregnancy. In Cancer obstetrics and Gynecology. Trimble EL, Trimble CL (eds). pp 157-176. 1999. Lippincott, Williams and Wilkins, Philadelphia, PA.
5. Bristow RE and Montz FJ. Cervical cancer. In Practical Strategies in Obsetrics and Gynecology. Dombrowski MP, McNeeley SG, Moghissi KS, Munkarah AR (eds). pp 458-470. 2000. W.B. Saunders Company, Philadelphia, PA.
6. Bristow RE and Montz FJ. Malignant tumors of the female genital tract. In The principles and practice of medicine, 24th edition. Stobo JD, Hellman DB, Ladenson PW, Petty BG, Traill (eds). 2001. Appleton and Lange, New York, NY.
7. Tomacruz RS, Bristow RE, Montz FJ. Management of Pelvic Hemorrhage. Surg Clin N Amer 2001; 81: 925-948.
8. Montz FJ, Bristow RE, Cundiff G. Female genital system. In Surgery: Scientific principles and practice. 2001 Lippincott Williams and Wilkins, Philadelphia, PA.
9. Montz FJ, Bristow RE. Management: Guidelines, Algorithms, and Consensus: Positive Margins in Colposcopy: Principles and Practice An Integrated Textbook and Atlas. Editors Apgar BS, Brotzman GL, Spitzer M. 2002. W.B. Saunders, Philadelphia, PA.
10. Huh J, Bristow RE. Cervical dysplasia. In the Johns Hopkins Handbook of Gynecology and Obstetrics. 2002. Lippincott Williams and Wilkins. Baltimore, MD.
11. Lambrou N, Bristow RE. Gestational trophoblastic neoplasia. In the Johns Hopkins Handbook of Gynecology and Obstetrics. 2002. Lippincott Williams and Wilkins. Baltimore, MD.
12. Dardik R, Duska LD, Bristow RE. Ovarian cancer. In the Johns Hopkins Handbook of Gynecology and Obstetrics. 2002. Lippincott Williams and Wilkins. Baltimore, MD.
13. Montz FJ, Bristow RE, Wheeless CR. Grafts for Wound Healing: a primer for the gynecologic surgeon. Operative Techniques in Gynecologic Surgery. 2001. W.B. Saunders Company, Philadelphia, PA.
14. Bristow RE, Montz FJ. The Role of Surgery in Advanced Endometrial Cancer. In Cancer of the Uterus. Rubin SC, Coukos G eds. 2004. Marcel Dekker Inc, New York, NY.
15. Bristow RE. Cervical Cancer. In Danforth’s Obstetrics and Gynecology, ninth edition. Scott J, Gibbs RS, Karlan BY, Haney A (eds). 2003. Lippincott Williams and Wilkins. Baltimore, MD.
16. Montz FJ, Bristow RE, del Carmen MG. Operative Injuries to the Ureter. In Telinde’s Operative Gynecology ninth edition. Rock JA, Thompson JD (eds). 2003. Lippincott Williams and Wilkins. Baltimore, MD.
17. Pataki I, Lanciano R, Bristow RE. Cancers of the Uterine Corpus: Management of Advanced Stage Endometrial Cancer. In Gynecologic Cancer: Controversies in Management. Gershenson DM, Gore M, McGuire WP, Quinn M, Thomas G eds. 2004. Elsevier Science. New York, NY.
18. Del Carmen MG, Bristow RE, Duska LR. Preoperative preparation and surgical instrumentation. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
19. Bristow RE, Lagasse LD. Cytoreductive surgery: pelvis. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
20. Giuntoli RL 2nd, Bristow RE, Schulick RD. Cytoreductive surgery: right upper abdomen. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
21. Coleman RL, Munkarah A, Bristow RE. Secondary cytoreductive surgery. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
22. Holschneider CH, Bristow RE, Montz FJ. Chemotherapy in pregnancy. In Chemotherapy for gynecological neoplasms. Benedetti-Panicci PL, Angioli R, Penalver M, Pecorelli S. editors. Marcel Dekker, Inc, New York, NY. 2005.
23. Lambrou N, Crisp M, Bristow R. Ovarian Cancer In H. Muss, K. Johnson, C. Hunter (eds): Comprehensive treatment and management of cancer in the elderly. Taylor and Francis Books Inc, New York, NY. 2006.
24. Diaz-Montes TP, Bristow RE. Borderline tumors of the ovary. In Textbook of Uncommon Cancers. Raghavan D, Brecher ML, Johnson DL, Meropol NJ, Moots P, Rose P. Eds. John Wiley and Sons Ltd., Chichester, West Sussex, UK. 2007.
25. Giuntoli RL II, Cundiff G, Bristow RE. Female Genitourinary anatomy and physiology. In Surgery: Scientific Principles and Practice. Lippincott Williams and Wilkins, Philadelphia, PA. 2006.
26. Giuntoli RL II, Huggins GR, Bristow RE. Early detection of gynecologic malignancy. In Principles of Ambulatory Medicine, 7th Ed. Barker LR, Burton JR, Zieve PD editors. Lippincott Williams and Wilkins, Philadelphia, PA, 2007.
27. Diaz-Montes TP, Bristow RE. Clinical predictors of outcome in epithelial ovarian carcinoma. In Prognostic and Predictive Factors in Gynecologic Oncology. Eds. Levenback C. Lu K, Coleman R, Sood A. 2007. Taylor and Francis Books Inc, New York, NY.
28. Giuntoli RL II. Bristow RE. Cervical Cancer. In Danforth’s Obstetrics and Gynecology, Tenth edition. Scott J, Gibbs RS, Karlan BY, Haney A (eds). 2007 Lippincott Williams and Wilkins. Baltimore, MD.
29. Guile M, Bristow RE. Management of Pelvic Hemorrhage. In The 5-Minute OB/GYN Clinical Consult. 2008. Lippincott Williams & Wilkins, Philadelphia PA.
30. Tanner E, Bristow RE. Ovarian Tumors, Borderline Malignancies. In The 5-Minute OB/GYN Clinical Consult. 2008. Lippincott Williams & Wilkins, Philadelphia PA.
31. Chi DS, Bristow RE, Gallup DG. Surgical principles in gynecologic oncology. In Principles and Practice of Gynecologic Oncology, Fourth Edition. 2009. Lippincott, Williams, and Wilkins, Philadelphia PA.
32. Eslamy H, Bristow R, Wahl RL. PET and PET/CT in ovarian cancer. In Principles And practice of PET and PET/CT 2nd Ed. 2009, Lippincott Williams and Wilkins, Philadelphia, PA.
33. Ibeanu OA, Bristow RE. Prognostic factors for gynecologic cancers. In Textbook of Gynecologic Oncology. 2009. Günes Publishing, Ankara, Turkey.
33. Ueda S, Bristow RE. Cytoreductive surgery in endometrial cancer and uterine sarcomas. In Cytoreductive surgery in gynecologic oncology: a multidisciplinary approach. Ed Yildirim Y. 2010: ISBN: 978-81-7895-484-4.
34. Jordan S, Bristow RE. Relapse – surgical considerations and secondary cytoreduction. In Management of Gynecologic Cancers in Older Women. Eds Lichtman S, Audisio R. Springer, New York, NY. 2012.
35. Obermair A, Ibeanu OA, Jandial DD, Armstrong DK, Bristow RE. Management of Acute and Chronic Complications of Gynecologic Cancer Treatment. In Principles and Practice of Gynecologic Oncology, 6th edition. Barakat R, Berchuck A, Markamn M, Randall M eds. Lippincott, Williams, and Wilkins, Philadelphia, PA 2013.
36. Bristow RE. Radical vulvectomy: en bloc radical vulvectomy, separate incision radical vulvectomy, wide radical excision of the vulva, and inguinofemoral lymphadenectomy. In Radical and Reconstructive Gynecologic Cancer Surgery. Bristow RE and Chi DS eds. 2015, McGraw-Hill. New York, NY.
37. Liu FW, Bristow RE, Tergas AI. Racial/ethnic disparities in gynecologic cancer screening, treatment, and survival. In Gynecologic Cancers: Genetic and epigenetic targets and drug development. In press, Springer, New York, NY.
38. Bristow RE. Surgery for ovarian cancer. In A Guide to Survivorship for Women Who Have Ovarian Cancer. In press, Johns Hopkins University Press, Baltimore, MD.
39. Bristow RE, Lagasse LD. Cytoreductive surgery: pelvis and radical oophorectomy. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
40. Lim MC, Bristow RE, Park SY. Cytoreductive surgery: right upper abdomen –diaphragm. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
41. Rose PG, Bristow RE, DeBernardo RL. Cytoreductive surgery: left upper quadrant. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
42. Chang SJ, Bristow RE, Chi DS, Ryu HS. Secondary cytoreductive surgery. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
1. Baldwin RL, Yamada SD, Bristow RE, Chen L, Karlan BY. Ovarian epithelial growth regulation. In Ovarian cancer 5, Sharp F, Blackett, Berek J, and Bast R (eds). Isis Medical Media, Oxford 1998: 99-107.
2. Bristow RE and Steren A: Cervical cancer. In The Johns Hopkins Handbook of Gynecology and Obstetrics. Lambrou NC, Morse AN, Wallach EE (eds). pp339-363. 1999. Lippincott, Williams and Wilkins, Phildelphia.
3. Bristow RE and Karlan BY. Disorders of the uterine cervix. In Danforth’s Obstetrics and Gynecology, eighth edition. Scott JR, DiSaia PJ, Hammond CB, Spellacy WN (eds). pp 805-836. 1999. JB Lippincott Company, Philadelphia.
4. Bristow RE and Montz FJ. Cervical cancer in pregnancy. In Cancer obstetrics and Gynecology. Trimble EL, Trimble CL (eds). pp 157-176. 1999. Lippincott, Williams and Wilkins, Philadelphia, PA.
5. Bristow RE and Montz FJ. Cervical cancer. In Practical Strategies in Obsetrics and Gynecology. Dombrowski MP, McNeeley SG, Moghissi KS, Munkarah AR (eds). pp 458-470. 2000. W.B. Saunders Company, Philadelphia, PA.
6. Bristow RE and Montz FJ. Malignant tumors of the female genital tract. In The principles and practice of medicine, 24th edition. Stobo JD, Hellman DB, Ladenson PW, Petty BG, Traill (eds). 2001. Appleton and Lange, New York, NY.
7. Tomacruz RS, Bristow RE, Montz FJ. Management of Pelvic Hemorrhage. Surg Clin N Amer 2001; 81: 925-948.
8. Montz FJ, Bristow RE, Cundiff G. Female genital system. In Surgery: Scientific principles and practice. 2001 Lippincott Williams and Wilkins, Philadelphia, PA.
9. Montz FJ, Bristow RE. Management: Guidelines, Algorithms, and Consensus: Positive Margins in Colposcopy: Principles and Practice An Integrated Textbook and Atlas. Editors Apgar BS, Brotzman GL, Spitzer M. 2002. W.B. Saunders, Philadelphia, PA.
10. Huh J, Bristow RE. Cervical dysplasia. In the Johns Hopkins Handbook of Gynecology and Obstetrics. 2002. Lippincott Williams and Wilkins. Baltimore, MD.
11. Lambrou N, Bristow RE. Gestational trophoblastic neoplasia. In the Johns Hopkins Handbook of Gynecology and Obstetrics. 2002. Lippincott Williams and Wilkins. Baltimore, MD.
12. Dardik R, Duska LD, Bristow RE. Ovarian cancer. In the Johns Hopkins Handbook of Gynecology and Obstetrics. 2002. Lippincott Williams and Wilkins. Baltimore, MD.
13. Montz FJ, Bristow RE, Wheeless CR. Grafts for Wound Healing: a primer for the gynecologic surgeon. Operative Techniques in Gynecologic Surgery. 2001. W.B. Saunders Company, Philadelphia, PA.
14. Bristow RE, Montz FJ. The Role of Surgery in Advanced Endometrial Cancer. In Cancer of the Uterus. Rubin SC, Coukos G eds. 2004. Marcel Dekker Inc, New York, NY.
15. Bristow RE. Cervical Cancer. In Danforth’s Obstetrics and Gynecology, ninth edition. Scott J, Gibbs RS, Karlan BY, Haney A (eds). 2003. Lippincott Williams and Wilkins. Baltimore, MD.
16. Montz FJ, Bristow RE, del Carmen MG. Operative Injuries to the Ureter. In Telinde’s Operative Gynecology ninth edition. Rock JA, Thompson JD (eds). 2003. Lippincott Williams and Wilkins. Baltimore, MD.
17. Pataki I, Lanciano R, Bristow RE. Cancers of the Uterine Corpus: Management of Advanced Stage Endometrial Cancer. In Gynecologic Cancer: Controversies in Management. Gershenson DM, Gore M, McGuire WP, Quinn M, Thomas G eds. 2004. Elsevier Science. New York, NY.
18. Del Carmen MG, Bristow RE, Duska LR. Preoperative preparation and surgical instrumentation. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
19. Bristow RE, Lagasse LD. Cytoreductive surgery: pelvis. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
20. Giuntoli RL 2nd, Bristow RE, Schulick RD. Cytoreductive surgery: right upper abdomen. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
21. Coleman RL, Munkarah A, Bristow RE. Secondary cytoreductive surgery. In Surgery for ovarian cancer: principles and practice. Bristow RE and Karlan BY eds. 2005. Taylor and Francis, London, UK.
22. Holschneider CH, Bristow RE, Montz FJ. Chemotherapy in pregnancy. In Chemotherapy for gynecological neoplasms. Benedetti-Panicci PL, Angioli R, Penalver M, Pecorelli S. editors. Marcel Dekker, Inc, New York, NY. 2005.
23. Lambrou N, Crisp M, Bristow R. Ovarian Cancer In H. Muss, K. Johnson, C. Hunter (eds): Comprehensive treatment and management of cancer in the elderly. Taylor and Francis Books Inc, New York, NY. 2006.
24. Diaz-Montes TP, Bristow RE. Borderline tumors of the ovary. In Textbook of Uncommon Cancers. Raghavan D, Brecher ML, Johnson DL, Meropol NJ, Moots P, Rose P. Eds. John Wiley and Sons Ltd., Chichester, West Sussex, UK. 2007.
25. Giuntoli RL II, Cundiff G, Bristow RE. Female Genitourinary anatomy and physiology. In Surgery: Scientific Principles and Practice. Lippincott Williams and Wilkins, Philadelphia, PA. 2006.
26. Giuntoli RL II, Huggins GR, Bristow RE. Early detection of gynecologic malignancy. In Principles of Ambulatory Medicine, 7th Ed. Barker LR, Burton JR, Zieve PD editors. Lippincott Williams and Wilkins, Philadelphia, PA, 2007.
27. Diaz-Montes TP, Bristow RE. Clinical predictors of outcome in epithelial ovarian carcinoma. In Prognostic and Predictive Factors in Gynecologic Oncology. Eds. Levenback C. Lu K, Coleman R, Sood A. 2007. Taylor and Francis Books Inc, New York, NY.
28. Giuntoli RL II. Bristow RE. Cervical Cancer. In Danforth’s Obstetrics and Gynecology, Tenth edition. Scott J, Gibbs RS, Karlan BY, Haney A (eds). 2007 Lippincott Williams and Wilkins. Baltimore, MD.
29. Guile M, Bristow RE. Management of Pelvic Hemorrhage. In The 5-Minute OB/GYN Clinical Consult. 2008. Lippincott Williams & Wilkins, Philadelphia PA.
30. Tanner E, Bristow RE. Ovarian Tumors, Borderline Malignancies. In The 5-Minute OB/GYN Clinical Consult. 2008. Lippincott Williams & Wilkins, Philadelphia PA.
31. Chi DS, Bristow RE, Gallup DG. Surgical principles in gynecologic oncology. In Principles and Practice of Gynecologic Oncology, Fourth Edition. 2009. Lippincott, Williams, and Wilkins, Philadelphia PA.
32. Eslamy H, Bristow R, Wahl RL. PET and PET/CT in ovarian cancer. In Principles And practice of PET and PET/CT 2nd Ed. 2009, Lippincott Williams and Wilkins, Philadelphia, PA.
33. Ibeanu OA, Bristow RE. Prognostic factors for gynecologic cancers. In Textbook of Gynecologic Oncology. 2009. Günes Publishing, Ankara, Turkey.
33. Ueda S, Bristow RE. Cytoreductive surgery in endometrial cancer and uterine sarcomas. In Cytoreductive surgery in gynecologic oncology: a multidisciplinary approach. Ed Yildirim Y. 2010: ISBN: 978-81-7895-484-4.
34. Jordan S, Bristow RE. Relapse – surgical considerations and secondary cytoreduction. In Management of Gynecologic Cancers in Older Women. Eds Lichtman S, Audisio R. Springer, New York, NY. 2012.
35. Obermair A, Ibeanu OA, Jandial DD, Armstrong DK, Bristow RE. Management of Acute and Chronic Complications of Gynecologic Cancer Treatment. In Principles and Practice of Gynecologic Oncology, 6th edition. Barakat R, Berchuck A, Markamn M, Randall M eds. Lippincott, Williams, and Wilkins, Philadelphia, PA 2013.
36. Bristow RE. Radical vulvectomy: en bloc radical vulvectomy, separate incision radical vulvectomy, wide radical excision of the vulva, and inguinofemoral lymphadenectomy. In Radical and Reconstructive Gynecologic Cancer Surgery. Bristow RE and Chi DS eds. 2015, McGraw-Hill. New York, NY.
37. Liu FW, Bristow RE, Tergas AI. Racial/ethnic disparities in gynecologic cancer screening, treatment, and survival. In Gynecologic Cancers: Genetic and epigenetic targets and drug development. In press, Springer, New York, NY.
38. Bristow RE. Surgery for ovarian cancer. In A Guide to Survivorship for Women Who Have Ovarian Cancer. In press, Johns Hopkins University Press, Baltimore, MD.
39. Bristow RE, Lagasse LD. Cytoreductive surgery: pelvis and radical oophorectomy. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
40. Lim MC, Bristow RE, Park SY. Cytoreductive surgery: right upper abdomen –diaphragm. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
41. Rose PG, Bristow RE, DeBernardo RL. Cytoreductive surgery: left upper quadrant. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
42. Chang SJ, Bristow RE, Chi DS, Ryu HS. Secondary cytoreductive surgery. In Surgery for Ovarian Cancer, 3rd edition. Bristow RE, Karlan BY, Chi DS eds. In press, CRC Press/Taylor & Francis, London, UK.
Grants
Ruth L. Kirchstein National Research Service Award - Gynecologic Oncology Fellowship Program
Sponsor: National Institutes of Health
Period: 2019 - 2021
Spatiotemporal analysis od disparities in ovarian cancer treatment and survival
Sponsor: National Institutes of Health
Period: 4/1/2016 - 12/31/2020
Professional Societies
American College of Surgeons, Fellow
Society of Surgical Oncology, Fellow
La Sociedad Mexicana de Oncologia A.C., Honorary Member
International Gynecologic Cancer Society, Member
Society of Gynecologic Oncologists, Full Member
Western Association of Gynecologic Oncologists, Member
American College of Obstetricians and Gynecologists, Fellow
American Society of Clinical Oncology, member
Link to this profile
https://faculty.uci.edu/profile/?facultyId=6111
https://faculty.uci.edu/profile/?facultyId=6111
Last updated
07/23/2020
07/23/2020